PA
KPTI icon

Profund Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Profund Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,168
Closed -$652K – 1102
2023
Q1 		$652K Buy
+11,168
New +$551K 0.04% 422

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Profund Advisors's KPTI Position: Q2 2023 in Review

Profund Advisors sold out of Karyopharm Therapeutics (KPTI) in Q2 2023, closing a stake of 11,168 shares — an estimated $652K sold.

Profund Advisors first reported a position in KPTI in Q1 2023 and held it in 1 quarter. The position peaked at $652K in Q1 2023. 137 funds tracked by Wall St. Rank hold KPTI as of Q2 2023.

  • Profund Advisors reported no remaining Karyopharm Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Profund Advisors sold 11,168 Karyopharm Therapeutics shares in Q2 2023, an estimated $652K.
  • Profund Advisors first reported a position in Karyopharm Therapeutics in Q1 2023 and held it in 1 quarter.
  • Profund Advisors's Karyopharm Therapeutics position peaked at $652K in Q1 2023.
  • 137 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2023.

Based on Profund Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.